Drugs / HIV-1 Immunogen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00001445 | Aug 1995 → Jul 2001 | HIV infectious disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00006153 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00021762 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00002173 | — | HIV infectious disease | The Immune Response Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-1 Immunogen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006153 ↗ |
| Known as | Remune | “An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.” NCT00002173 ↗ |
| Modality | Vaccine | “A vaccine called Remune works to stop the virus infection” NCT00006153 ↗ |
| Route | Intramuscular | “HIV-1 Immunogen intramuscularly at 0, 3, 6, 9, and 12 months” NCT00001445 ↗ |